Gene Expression Meta-Analysis Identifies VDAC1 as a Predictor of Poor Outcome in Early Stage Non-Small Cell Lung Cancer

被引:46
|
作者
Grills, Claire [1 ]
Jithesh, Puthen V. [1 ]
Blayney, Jaine [1 ]
Zhang, Shu-Dong [1 ]
Fennell, Dean A. [1 ,2 ]
机构
[1] Queens Univ Belfast, Ctr Biomed Informat, Belfast, Antrim, North Ireland
[2] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast, Antrim, North Ireland
来源
PLOS ONE | 2011年 / 6卷 / 01期
关键词
POSITRON-EMISSION-TOMOGRAPHY; VINORELBINE PLUS CISPLATIN; DEPENDENT ANION CHANNEL; CYTOCHROME-C; PROGNOSTIC VALUE; HEXOKINASE-II; BINDING; MITOCHONDRIA; ACTIVATION; MORTALIN;
D O I
10.1371/journal.pone.0014635
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: The bioenergetic status of non-small cell lung cancer correlates with tumour aggressiveness. The voltage dependent anion channel type 1 (VDAC1) is a component of the mitochondrial permeability transition pore, regulates mitochondrial ATP/ADP exchange suggesting that its over-expression could be associated with energy dependent processes including increased proliferation and invasiveness. To test this hypothesis, we conducted an in vivo gene-expression meta-analysis of surgically resected non-small cell lung cancer (NSCLC) using 602 individual expression profiles, to examine the impact of VDAC1 on survival. Methodology/Principal Findings: High VDAC1 expression was associated with shorter overall survival with hazard ratio (HR) = 0.6639 (95% confidence interval (CI) 0.4528 to 0.9721), p = 0.035352 corresponding to 52 versus 101 months. VDAC1 predicted shorter time to recurrence and was shown to be an independent prognostic factor compared with histology, gender, age, nodal stage and tumour stage in a Cox multivariate analysis. Supervised analysis of all the datasets identified a 6-gene signature comprising HNRNPC, HSPA4, HSPA9, UBE2D2, CSNK1A1 and G3BP1 with overlapping functions involving regulation of protein turnover, RAS-RAF-MEK pathway and transcription. VDAC1 predicted survival in breast cancer and myeloma and an unsupervised analysis revealed enrichment of the VDAC1 signature in specific subsets. Conclusions: In summary, gene expression analysis identifies VDAC1 gene expression as a predictor of poor outcome in NSCLC and other cancers and is associated with dysregulation of a conserved set of biological pathways, which may be causally associated with aggressive tumour behaviour.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Mortalin overexpression predicts poor prognosis in early stage of non-small cell lung cancer
    Sun, Jie
    Che, Shuan-Long
    Piao, Jun-Jie
    Xu, Ming
    Chen, Li-Yan
    Lin, Zhen-Hua
    TUMOR BIOLOGY, 2017, 39 (03)
  • [2] Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer
    Traynor, Anne M.
    Weigel, Tracey L.
    Oettel, Kurt R.
    Yang, David T.
    Zhang, Chong
    Kim, KyungMann
    Salgia, Ravi
    Iida, Mari
    Brand, Toni M.
    Hoang, Tien
    Campbell, Toby C.
    Hernan, Hilary It
    Wheelerg, Deric L.
    LUNG CANCER, 2013, 81 (01) : 138 - 141
  • [3] The Prognostic Value of Phosphorylated AKT Expression in Non-Small Cell Lung Cancer: A Meta-Analysis
    Qiu, Zhi-Xin
    Zhang, Kui
    Qiu, Xue-Song
    Zhou, Min
    Li, Wei-Min
    PLOS ONE, 2013, 8 (12):
  • [4] Decreased expression of FOXF2 as new predictor of poor prognosis in stage I non-small cell lung cancer
    Kong, Peng-Zhou
    Li, Guang-Ming
    Tian, Yin
    Song, Bin
    Shi, RuYi
    ONCOTARGET, 2016, 7 (34) : 55601 - 55610
  • [5] Prognostic value of the expression of estrogen receptor β in patients with non-small cell lung cancer: a meta-analysis
    Ma, Lihong
    Zhan, Ping
    Liu, Yafang
    Zhou, Zejun
    Zhu, Qingqing
    Miu, Yingying
    Wang, Xiaoxia
    Jin, Jiajia
    Li, Qian
    Lv, Tangfeng
    Song, Yong
    TRANSLATIONAL LUNG CANCER RESEARCH, 2016, 5 (02) : 202 - 207
  • [6] Targeted Therapy in Early Stage Non-small Cell Lung Cancer
    Liu, Si-Yang
    Liu, Si-Yang Maggie
    Zhong, Wen-Zhao
    Wu, Yi-Long
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2022, 23 (09) : 1169 - 1184
  • [7] CYFRA21-1 tests in the diagnosis of non-small cell lung cancer: A meta-analysis
    Fu, Lei
    Wang, Rong
    Yin, Ling
    Shang, Xiaopu
    Zhang, Runtong
    Zhang, Pengjun
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2019, 34 (03) : 251 - 261
  • [8] Prognostic and clinicopathological significance of NRF2 expression in non-small cell lung cancer: A meta-analysis
    Wang, Qingsong
    Xu, Liang
    Wang, Gang
    Chen, Lei
    Li, Changping
    Jiang, Xiangli
    Gao, Hai
    Yang, Bing
    Tian, Weiping
    PLOS ONE, 2020, 15 (11):
  • [9] Overexpression of the Mammalian Target of Rapamycin A Novel Biomarker for Poor Survival in Resected Early Stage Non-small Cell Lung Cancer
    Dhillon, Tony
    Mauri, Francesco A.
    Bellezza, Guido
    Cagini, Lucio
    Barbareschi, Mattia
    North, Bernard V.
    Seckl, Michael J.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (03) : 314 - 319
  • [10] APOPTOSIS GENE EXPRESSION PROFILE IN EARLY-STAGE NON SMALL CELL LUNG CANCER
    Metodieva, S. N.
    Cherneva, R., V
    Nikolova, D. N.
    Genchev, G. D.
    Petrov, D. B.
    Toncheva, D., I
    BALKAN JOURNAL OF MEDICAL GENETICS, 2010, 13 (02) : 47 - 52